BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders
BioAdaptives Inc. (OTC: BDPT) has received FINRA approval for a dividend distribution to common stock shareholders. The dividend will be payable on January 22, 2025, with an Ex-dividend Date of January 23, 2025. The distribution excludes preferred stockholders.
Shareholders holding stock in certificate or book entry form with the transfer agent will receive confirmation letters for their new stock issuance in book entry form. CEO James Keener expressed gratitude to shareholders for their support and confidence in the company's vision to revolutionize health and wellness. The company continues to focus on developing innovative health solutions and expanding its market presence both domestically and internationally.
BioAdaptives Inc. (OTC: BDPT) ha ricevuto l'approvazione da parte di FINRA per la distribuzione di dividendi agli azionisti delle azioni ordinarie. Il dividendo sarà pagabile il 22 gennaio 2025, con una data Ex-dividendo del 23 gennaio 2025. La distribuzione esclude gli azionisti delle azioni privilegiate.
Gli azionisti in possesso di certificati azionari o di azioni in forma contabile con l'agente di trasferimento riceveranno lettere di conferma per la loro nuova emissione azionaria in forma contabile. Il CEO James Keener ha espresso gratitudine agli azionisti per il loro supporto e la fiducia nella visione dell'azienda di rivoluzionare la salute e il benessere. L'azienda continua a concentrarsi sullo sviluppo di soluzioni sanitarie innovative ed espandere la propria presenza sul mercato sia a livello nazionale che internazionale.
BioAdaptives Inc. (OTC: BDPT) ha recibido la aprobación de FINRA para la distribución de dividendos a los accionistas de acciones comunes. El dividendo será pagadero el 22 de enero de 2025, con una fecha Ex-dividendo del 23 de enero de 2025. La distribución excluye a los accionistas preferentes.
Los accionistas que posean acciones en forma de certificado o en cuenta con el agente de transferencia recibirán cartas de confirmación para su nueva emisión de acciones en forma contable. El CEO James Keener expresó su agradecimiento a los accionistas por su apoyo y confianza en la visión de la empresa para revolucionar la salud y el bienestar. La empresa continúa enfocándose en desarrollar soluciones sanitarias innovadoras y en ampliar su presencia en el mercado tanto a nivel nacional como internacional.
BioAdaptives Inc. (OTC: BDPT)는 보통주 주주를 위한 배당 분배에 대한 FINRA 승인을 받았습니다. 배당금은 2025년 1월 22일에 지급되며, 배당락일은 2025년 1월 23일입니다. 분배는 우선주 주주를 제외합니다.
증서 또는 계좌 형태로 주식을 보유한 주주는 새로운 주식 발행에 대한 확인서를 수령하게 됩니다. CEO 제임스 키너는 회사의 비전에 대한 지지와 신뢰에 감사의 말을 전했습니다. 회사는 혁신적인 건강 솔루션 개발과 국내외에서 시장 존재감을 확장하는 데 계속 집중하고 있습니다.
BioAdaptives Inc. (OTC: BDPT) a reçu l'approbation de FINRA pour la distribution de dividendes aux actionnaires d'actions ordinaires. Le dividende sera payable le 22 janvier 2025, avec une date de détachement du dividende le 23 janvier 2025. La distribution exclut les actionnaires d'actions privilégiées.
Les actionnaires détenant des actions sous forme de certificat ou de compte auprès de l'agent de transfert recevront des lettres de confirmation pour leur nouvelle émission d'actions sous forme de compte. Le PDG James Keener a exprimé sa gratitude envers les actionnaires pour leur soutien et leur confiance dans la vision de l'entreprise de révolutionner la santé et le bien-être. L'entreprise continue de se concentrer sur le développement de solutions de santé innovantes et sur l'expansion de sa présence sur le marché tant au niveau national qu'international.
BioAdaptives Inc. (OTC: BDPT) hat die FINRA-Zulassung für die Ausschüttung von Dividenden an die Aktionäre der Stammaktien erhalten. Die Dividende wird am 22. Januar 2025 ausgezahlt, mit einem Ex-Dividenden-Datum am 23. Januar 2025. Die Ausschüttung schließt Vorzugsaktionäre aus.
Aktionäre, die Aktien in Zertifikats- oder Buchform beim Übertragungsagenten halten, erhalten Bestätigungsschreiben für ihre neue Aktienausgabe in Buchform. CEO James Keener drückte seine Dankbarkeit gegenüber den Aktionären für deren Unterstützung und Vertrauen in die Vision des Unternehmens aus, die Gesundheit und das Wohlbefinden zu revolutionieren. Das Unternehmen konzentriert sich weiterhin auf die Entwicklung innovativer Gesundheitslösungen und die Erweiterung seiner Marktpräsenz sowohl national als auch international.
- FINRA approval received for dividend distribution
- Demonstrates financial capacity to return value to shareholders
- None.
LAS VEGAS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives Inc. (OTC: BDPT), a forward-thinking innovator in health and wellness solutions, is pleased to announce that FINRA has approved a dividend to its common stock shareholders. The decision to issue the dividend reflects the company’s gratitude for the unwavering support of its shareholders and their confidence in BioAdaptives’ mission and growth trajectory. Dividends were only paid to common stockholders, not to preferred stockholders.
The dividend will be payable on January 22, 2025, and the Ex-dividend Date is January 23, 2025. Shareholders are encouraged to consult with their brokers or financial advisors for details on dividend distribution. Shareholders who hold their stock either in certificate or book entry form with the transfer agent will receive a letter confirming that their new stock has been issued and will be in book entry.
“This dividend is a heartfelt thank you to our shareholders who have stood by us through our journey,” said James Keener, CEO of BioAdaptives, Inc. “Your confidence in our vision to revolutionize health and wellness has been integral to our progress. This gesture underscores our appreciation and reaffirms our commitment to delivering long-term value as we advance our product portfolio and market reach.”
BioAdaptives continues to deliver innovative, science-backed solutions designed to enhance human and animal health. With a pipeline of promising products and partnerships, the company is poised for continued growth in both domestic and international markets.
James Keener added, “This is an exciting time for BioAdaptives. Our recent advancements and the ongoing support of our shareholders inspire us to work harder every day. We remain steadfast in our dedication to improving lives while creating sustainable value for all stakeholders.”
About BioAdaptives, Inc.
BioAdaptives, Inc. (OTC: BDPT) is a leading innovator in the health and wellness industry, dedicated to developing and marketing nutraceutical and wellness products that harness the power of natural ingredients and cutting-edge science. Our mission is to improve the quality of life for our customers by offering products that support optimal health and vitality.
For more information about Xcellara™ Stem Cell Activator and other BioAdaptives products, please visit our website at www.bioadaptives.com.
Contact Information:
BioAdaptives, Inc.
Emily Harrison
IR Coordinator
(702)-659-8829
info@bioadaptives.com
2620 Regatta Dr, Suite 102
Las Vegas, NV 89128
Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, statements regarding expected growth, potential benefits of the company's products, and future business opportunities. These statements involve risks, uncertainties, and other factors that may cause actual results or developments to differ materially from those expressed or implied.
Wire Service Contact:
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
FAQ
When will BioAdaptives (BDPTD) pay its dividend in 2025?
Are BioAdaptives (BDPTD) preferred stockholders eligible for the 2025 dividend?
How will BioAdaptives (BDPTD) shareholders receive confirmation of their dividend?
What is the Ex-dividend date for BioAdaptives (BDPTD) 2025 dividend?
